Roche to pay out 50m for Memory Pharmaceuticals

摘要

Roche is to acquire all the outstanding shares of Memory Pharmaceuticals in a cash transaction worth approximately US50m(euro 35.5m).Memory Pharmaceuticals develops drug candidates for treatment of central nervous system(CNS)disorders such as Alzheimer's disease and schizophrenia.The company's nicotinic alpha-7 agonist drug candidates in these disease areas are already in partnered programmes with Roche:R3487/MEM 3454 is in phase II clinical trials for Alzheimer's disease and schizophrenia;and R4996/MEM 63908 is in phase I for Alzheimer's disease.